Consensus enGene Holdings Inc.

Equities

ENGN

CA29286M1059

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
13.62 ^USD	-4.35%		-4.29%	+47.56%

May. 15	EnGene Holdings Inc. Approves Board Appointments	CI
Apr. 22	Wells Fargo Starts enGene Holdings With Overweight Rating, $30 Price Target	MT

Evolution of the average Target Price on enGene Holdings Inc.

Price target over the last 5 years

History of analyst recommendation changes

547847505938cfbc9.kDloUWqnamcgq_JJACF2h6uSoZdzRl9zY3ThUdHZ6Mw.40AdEz31WVFv3Z4TdVIf4-bc-PpEPjYCKDKNN7qNi4uhWiE5AclYBkL9sw~241ab7720fae8eaff90d004745c9a93b

Analyst Recommendations on enGene Holdings Inc.

Wells Fargo Starts enGene Holdings With Overweight Rating, $30 Price Target	Apr. 22	MT
Guggenheim Starts enGene Holdings With Buy Rating, $34 Price Target	Apr. 15	MT
UBS Initiates Coverage on enGene Holdings With Buy Rating, $37 Price Target	Mar. 28	MT
Morgan Stanley Starts Coverage on Engene With Overweight Rating, $40 Price Target	Mar. 08	MT
Leerink Partners Starts enGene Holdings With Outperform Rating, $31 Price Target	Feb. 20	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.98 USD

Average target price

34.4 USD

Spread / Average Target

+165.02%

High Price Target

40 USD

Spread / Highest target

+208.17%

Low Price Target

30 USD

Spread / Lowest Target

+131.12%

Consensus detail

Consensus revision (last 18 months)

Analysts covering enGene Holdings Inc.

Wells Fargo Securities
Guggenheim
UBS
Morgan Stanley
Leerink Partners

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar